Company Shares of ABIOMED (NASDAQ:ABMD) Rally 3.61%

ABIOMED (NASDAQ:ABMD) : Traders are bullish on ABIOMED (NASDAQ:ABMD) as it has outperformed the S&P 500 by a wide margin of 9.56% in the past 4 weeks. The bullishness in the stock continues even in the near-term as the stock has returned an impressive 2.3%, relative to the S&P 500. The stock has continued its bullish performance both in the near-term and the medium-term, as the stock is up 3.61% in the last 1 week, and is up 11.33% in the past 4 weeks. Buying continues as the stock moves higher, suggesting a strong appetite for the stock.

The company shares have rallied 68.09% from its 1 Year high price. On Jul 8, 2016, the shares registered one year high at $115.89 and the one year low was seen on Jul 15, 2015. The 50-Day Moving Average price is $103.32 and the 200 Day Moving Average price is recorded at $92.75.

The stock has recorded a 20-day Moving Average of 9.12% and the 50-Day Moving Average is 13.26%.


ABIOMED (NASDAQ:ABMD): stock turned positive on Friday. Though the stock opened at $114.08, the bulls momentum made the stock top out at $115.89 level for the day. The stock recorded a low of $112.86 and closed the trading day at $114.15, in the green by 0.55%. The total traded volume for the day was 645,893. The stock had closed at $113.53 in the previous days trading.

In an insider trading activity, According to the information disclosed by the Securities and Exchange Commission in a Form 4 filing, the Officer (Vp, Global Sales & Marketing) of ABIOMED INC, Howley Michael G had sold 10,000 shares worth of $1,065,800 in a transaction dated June 29, 2016. In this transaction, 10,000 shares were sold at $106.58 per share.

Abiomed, Inc. is a provider of temporary percutaneous mechanical circulatory support devices. The Company offers care to heart failure patients. The Companys products include Impella 2.5, a percutaneous micro heart pump with an integrated motor and sensors; Impella CP, which is primarily used by either interventional cardiologists to support patients in the catheter lab or by surgeons in the heart surgery suite; Impella 5.0 and Impella LD, a percutaneous micro heart pumps with integrated motors and sensors for use primarily in the heart surgery suite; Impella RP, a percutaneous catheter-based axial flow pump that is designed to allow greater than four liters of flow per minute; AB5000, a circulatory support system for the temporary support of acute heart failure patients in profound shock, and Symphony, a minimally invasive implantable cardiac assist device.

Leave a Reply

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.